CONMED (CNMD)
(Delayed Data from NYSE)
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market. However, rising pricing pressure remains a concern.
Here's Why You Should Hold on to Varian (VAR) Stock for Now
by Zacks Equity Research
Varian (VAR) gains from Oncology unit, deals with weakness in the Proton Therapy segment.
Here's Why You Should Hold on to Pacific Biosciences Stock
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.
Here's Why You Should Hold on to OPKO Health (OPK) Stock Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
Haemonetics Launches TEG 6s PlateletMapping Assay Cartridge
by Zacks Equity Research
The global commercial availability of the cartridge is likely to bolster Haemonetics' (HAE) TEG portfolio.
Tandem Diabetes Gets Canadian Nod for t:slim X2 Insulin Pump
by Zacks Equity Research
This regulatory clearance is expected to accelerate Tandem Diabetes' (TNDM) global pump shipments and expand its customer base.
Here's Why You Should Hold on to Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) raises 2019 revenue and EPS guidance.
Here's Why You Should Retain PRA Health (PRAH) Stock Now
by Zacks Equity Research
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, escalating direct costs remain a woe.
Here's Why Conmed (CNMD) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cooper Companies' CVI Unit Gets FDA Nod, To Boost Eye Health
by Zacks Equity Research
Cooper Companies' (COO) CVI Unit has receives FDA approval for its MiSight 1 day contact lens, which complements its commitment to eye health innovation.
Here's Why You Should Hold on to Becton, Dickinson Stock Now
by Zacks Equity Research
Becton, Dickinson (BDX) expects tariffs to impact its bottom line in first-quarter fiscal 2020.
Here's Why You Should Hold on to PerkinElmer Stock for Now
by Zacks Equity Research
PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
BD's Onclarity HPV PMA Submission to Boost Women's Health
by Zacks Equity Research
Becton, Dickinson (BDX) offers a wide range of next-generation solutions in the field of cervical, ovarian and breast cancer.
Here's Why You Should Hold Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.
NextGen's Medfusion Buyout to Improve Patient Experience
by Zacks Equity Research
NextGen (NXGN) showcases new capabilities and services for its flagship NextGen Enterprise platform.
Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why Conmed (CNMD) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Conmed (CNMD) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Conmed (CNMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CONMED (CNMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) Q3 earnings gain from higher revenues, solid segmental performance and margin expansion. However, high long-term debt remains a concern.
Conmed (CNMD) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 10.71% and 2.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) raises 2019 revenue and earnings per share guidance.
XRAY vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Retain HMS Holdings (HMSY) Stock For Now
by Zacks Equity Research
HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services as well as robust margins despite intense competition.